Real-world effectiveness data published in 2025, following fezolinetant’s regulatory approval as the first neurokinin-3 receptor antagonist for menopausal vasomotor symptoms, has confirmed the strong efficacy seen in earlier clinical trials now translates effectively into routine clinical practice, offering women a genuinely new non-hormonal option for managing hot flashes and night sweats. The arrival of a genuinely effective non-hormonal option represents a significant development for the substantial proportion of women globally, and across Dubai specifically, who either cannot use HRT due to medical contraindications or simply prefer to avoid hormonal treatment, a group that has historically had access to comparatively limited and often less effective alternatives.
What Fezolinetant Is and How It Works
Fezolinetant works through an entirely different mechanism than previous non-hormonal options such as SSRIs or gabapentin. It directly targets the neurokinin-3 receptor pathway in the brain’s thermoregulatory centre — the same pathway disrupted by oestrogen withdrawal during menopause — to reduce the frequency and severity of hot flashes without involving hormones at all.
What the 2025 Real-World Data Shows
The new data, drawn from over 5,000 women treated in routine clinical settings rather than controlled trial conditions, confirmed reductions in hot flash frequency and severity consistent with the original pivotal trials, alongside good tolerability and a low discontinuation rate due to side effects.
Who This Option Is Particularly Relevant For
This medication is especially valuable for women who cannot or prefer not to use hormone replacement therapy — including women with a history of hormone-receptor-positive breast cancer, certain clotting disorders, or simply a strong personal preference to avoid hormonal treatment. For these women across World Trade Centre, Jumeirah, and the wider Dubai community, previous non-hormonal options often provided only partial relief.
What to Discuss With Your Specialist
Women experiencing significant vasomotor symptoms who are not candidates for, or who prefer to avoid, HRT should discuss fezolinetant as a specific, evidence-backed treatment option with their menopause specialist, alongside a full review of liver function testing requirements, which are part of the standard monitoring protocol for this medication.
What to Discuss With Your Specialist
As with any newly approved medication, ongoing post-marketing surveillance continues to refine understanding of fezolinetant’s long-term safety profile, including the liver function monitoring that is currently recommended during treatment. Women considering this option should expect their specialist to discuss this monitoring requirement clearly, along with realistic expectations about the degree of symptom improvement typically achieved, which — while substantial for many women — does not always match the symptom elimination some women experience with HRT.
How This Compares to Current Standard Practice in Dubai
Non-hormonal menopause treatment options are increasingly discussed across Dubai’s menopause-focused clinics, particularly for women with contraindications to HRT. As fezolinetant becomes more widely available regionally, it is expected to become a standard part of this non-hormonal discussion.
Frequently Asked Questions
Is fezolinetant a hormone?
Is fezolinetant available for menopause treatment in Dubai?
How does fezolinetant compare in effectiveness to HRT for hot flashes?
Conclusion
The expanding range of effective non-hormonal menopause treatments means more women than ever can find meaningful symptom relief, regardless of their suitability for HRT. Dr. Ruby Rashmi keeps pace with these emerging options to provide every patient in Dubai with the full range of evidence-based menopause care.
Sources & References
This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing:
- Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk
- American College of Obstetricians and Gynecologists (ACOG) — acog.org
- International Federation of Gynecology and Obstetrics (FIGO) — figo.org
- World Health Organization (WHO) — who.int
- National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk
- American Society for Reproductive Medicine (ASRM) — asrm.org
- European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu
⚠ IMPORTANT DISCLAIMER
This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment.
No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition.
Consult Dr. Ruby Rashmi
Specialist Obstetrician & Gynecologist, Dubai. Explore personalised menopause care with the latest evidence-based hormonal and non-hormonal treatment options tailored to your needs.
